Revisiting the cognitive potential of lithium in alzheimer's disease: the role of cholinergic system and brain connectivity.

Authors

Lorenzo Pini, Bruno Pietro Imbimbo, Nunzio Pomara

Published in

Translational psychiatry. Jul 20, 2026. Epub Jul 20, 2026.

Abstract

Recent evidence demonstrating a marked reduction in endogenous brain lithium levels in mild cognitive impairment and Alzheimer's disease (AD) has renewed interest in lithium as a physiological modulator of brain aging and neurodegeneration. Experimental data indicate that lithium deficiency accelerates amyloid-β deposition, tau pathology, synaptic and myelin loss, whereas physiological lithium replacement mitigates neuropathology and cognitive decline. Here, we argue that lithium's cognitive potential in AD has been underestimated due to the historical neglect of two interrelated mechanisms: modulation of the cholinergic system and preservation of brain connectivity. Lithium has long been shown to inhibit cholinesterase activity and to increase choline and glycine availability, suggesting a capacity to enhance central cholinergic tone. Given the established role of cholinergic dysfunction in AD, this mechanism may represent an unrecognized contributor to lithium's neurocognitive effects. In parallel, converging human neuroimaging evidence indicates that lithium modulates functional brain networks and is associated with improved white matter integrity, supporting a role in maintaining structural and functional connectivity. We propose brain connectivity as a systems-level integrator of lithium's effects on synaptic plasticity, neuroinflammation, myelination, and cholinergic signaling. Future trials in early AD should incorporate physiological-dose lithium, candidate cholinergic biomarkers, and multimodal connectivity imaging to clarify lithium's translational potential as a network-stabilizing intervention. To bridge prior clinical disappointments and the renewed lithium hypothesis, we further propose a de-risked trial strategy centered on biomarker-confirmed early disease, physiological-dose exposure, structured safety surveillance, and imaging-based target engagement.

PMID:
42477313
Bibliographic data and abstract were imported from PubMed on 21 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.